Loading market event…
Loading market event…
Worth noting Market event Mon, Nov 16 1 min read
On November 16, 2026, Helus Pharma announced positive topline, or initial headline, results from APPROACH, its Phase 3 trial of HLP003 in adults with major depressive disorder. Phase 3 trials provide key evidence for regulatory review; this study tested HLP003 as an addition to existing treatment. HLP003 is deuterated psilocin, a psychedelic-derived drug candidate that acts on serotonin receptors.[1]
Helus said the HLP003 group had a 7.6-point greater reduction than placebo at week 6 on the Montgomery-Asberg Depression Rating Scale, or MADRS, which measures depression severity. The difference remained 7.0 points at week 12; lower scores mean fewer symptoms. These were the primary and a key secondary measure of effectiveness, respectively, and both results were statistically significant. The company also reported significant improvement as early as day 2 and said HLP003 was generally well tolerated. The announcement presents initial headline results.[1]
For Helus and potential pharmaceutical partners, the results reduce uncertainty about whether HLP003 can improve depression symptoms and give them stronger grounds to commit further development resources. Early relief and a benefit sustained through week 12 could make the add-on treatment more appealing to doctors and health insurers.[1]
The path to revenue still depends on complete efficacy and safety data, regulatory approval, coverage and actual use after launch. The company's description of the drug as generally well tolerated is preliminary; the supplied results do not establish specific side effects, treatment-delivery costs or sales potential.[1]
Potential pharmaceutical partners now have stronger efficacy evidence for assessing HLP003. Rival developers gain a new clinical benchmark, but must establish their own drugs' effectiveness and safety in separate trials.[1]